Zomedica Reports Record Fourth Quarter Revenue

Zomedica Corp., an animal health company, achieved record fourth quarter revenue of $10.5 million, marking a 33% increase from the previous year. The company also reported a full-year revenue of $32 million for 2025, reflecting a 17% growth compared to 2024. This marks the 20th consecutive quarter of year-over-year revenue growth for Zomedica, highlighting strong demand for its PulseVet® and Assisi® therapeutic devices and expanding TRUFORMA® platform.

CEO Larry Heaton emphasized the company's strategic long-term approach and noted a significant milestone of surpassing $10 million in quarterly sales for the first time. Notably, the Development Services segment generated $3.1 million in revenue, opening new opportunities. Despite a net loss of $81.9 million for the year, Zomedica maintained a strong liquidity position with $53.3 million.

The gross margin increased to 69% in the fourth quarter, showcasing effective cost management, with operating expenses down by $1.4 million from the previous year. The company remains optimistic about future growth as it continues to emphasize global adoption and strives for profitability in the upcoming year.